Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement.

In: The Journal of rheumatology · 1983 · vol. 10(5) , pp. 682–7 · PMID:6606038 · W2404201322
article OA: closed CC0 ⤵ 21 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-08

Danazol treatment of seven systemic lupus erythematosus patients showed decreases in DNA antibodies, increases in complement and platelets, and clinical improvement, suggesting potential benefits for mildly active SLE and thrombocytopenia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Seven patients with systemic lupus erythematosus (SLE) were treated with Danazol in a controlled study. Phenomena observed in some patients treated with Danazol were: 1) decrease in immunoglobulins and antibodies to native DNA; 2) increases in serum complement and platelets; and 3) clinical improvement. Ineffective drug trials were associated with increasing disease activity. Drug side effects were minimal. It appears that the drug may have an ameliorative effect on mildly active SLE patients and sometimes a marked effect on thrombocytopenia. Further evaluation of Danazol appears to be warranted for these types of patients but not for treatment of acute or severe forms of the disease.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (19)

Source provenance

openalex
last seen: 2026-05-10T11:02:40.850500+00:00
License: CC0 · commercial use OK